Cargando…

Topical retapamulin in the management of infected traumatic skin lesions

Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents that target the ribosome...

Descripción completa

Detalles Bibliográficos
Autores principales: Shawar, Ribhi, Scangarella-Oman, Nicole, Dalessandro, MaryBeth, Breton, John, Twynholm, Monique, Li, Gang, Garges, Harmony
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697516/
https://www.ncbi.nlm.nih.gov/pubmed/19436611
_version_ 1782168332533760000
author Shawar, Ribhi
Scangarella-Oman, Nicole
Dalessandro, MaryBeth
Breton, John
Twynholm, Monique
Li, Gang
Garges, Harmony
author_facet Shawar, Ribhi
Scangarella-Oman, Nicole
Dalessandro, MaryBeth
Breton, John
Twynholm, Monique
Li, Gang
Garges, Harmony
author_sort Shawar, Ribhi
collection PubMed
description Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents that target the ribosome or ribosomal factors, minimizing the potential for target-specific cross-resistance with other antibacterial classes in current use. In vitro studies show that retapamulin has high potency against the Gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes, and coagulase-negative staphylococci) commonly found in skin and skin-structure infections (SSSIs), including S. aureus strains with resistance to agents such as macrolides, fusidic acid, or mupirocin, and other less common organisms associated with SSSIs, anaerobes, and common respiratory tract pathogens. Clinical studies have shown that twice-daily topical retapamulin for 5 days is comparable to 10 days of oral cephalexin in the treatment of secondarily infected traumatic lesions. A 1% concentration of retapamulin ointment has been approved for clinical use as an easily applied treatment with a short, convenient dosing regimen for impetigo. Given the novel mode of action, low potential for cross-resistance with established antibacterial agents, and high in vitro potency against many bacterial pathogens commonly recovered from SSSIs, retapamulin is a valuable enhancement over existing therapeutic options.
format Text
id pubmed-2697516
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26975162009-06-17 Topical retapamulin in the management of infected traumatic skin lesions Shawar, Ribhi Scangarella-Oman, Nicole Dalessandro, MaryBeth Breton, John Twynholm, Monique Li, Gang Garges, Harmony Ther Clin Risk Manag Review Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents that target the ribosome or ribosomal factors, minimizing the potential for target-specific cross-resistance with other antibacterial classes in current use. In vitro studies show that retapamulin has high potency against the Gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes, and coagulase-negative staphylococci) commonly found in skin and skin-structure infections (SSSIs), including S. aureus strains with resistance to agents such as macrolides, fusidic acid, or mupirocin, and other less common organisms associated with SSSIs, anaerobes, and common respiratory tract pathogens. Clinical studies have shown that twice-daily topical retapamulin for 5 days is comparable to 10 days of oral cephalexin in the treatment of secondarily infected traumatic lesions. A 1% concentration of retapamulin ointment has been approved for clinical use as an easily applied treatment with a short, convenient dosing regimen for impetigo. Given the novel mode of action, low potential for cross-resistance with established antibacterial agents, and high in vitro potency against many bacterial pathogens commonly recovered from SSSIs, retapamulin is a valuable enhancement over existing therapeutic options. Dove Medical Press 2009 2009-03-26 /pmc/articles/PMC2697516/ /pubmed/19436611 Text en © 2009 Shawar et al, publisher and licensee Dove Medical Press Ltd.
spellingShingle Review
Shawar, Ribhi
Scangarella-Oman, Nicole
Dalessandro, MaryBeth
Breton, John
Twynholm, Monique
Li, Gang
Garges, Harmony
Topical retapamulin in the management of infected traumatic skin lesions
title Topical retapamulin in the management of infected traumatic skin lesions
title_full Topical retapamulin in the management of infected traumatic skin lesions
title_fullStr Topical retapamulin in the management of infected traumatic skin lesions
title_full_unstemmed Topical retapamulin in the management of infected traumatic skin lesions
title_short Topical retapamulin in the management of infected traumatic skin lesions
title_sort topical retapamulin in the management of infected traumatic skin lesions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697516/
https://www.ncbi.nlm.nih.gov/pubmed/19436611
work_keys_str_mv AT shawarribhi topicalretapamulininthemanagementofinfectedtraumaticskinlesions
AT scangarellaomannicole topicalretapamulininthemanagementofinfectedtraumaticskinlesions
AT dalessandromarybeth topicalretapamulininthemanagementofinfectedtraumaticskinlesions
AT bretonjohn topicalretapamulininthemanagementofinfectedtraumaticskinlesions
AT twynholmmonique topicalretapamulininthemanagementofinfectedtraumaticskinlesions
AT ligang topicalretapamulininthemanagementofinfectedtraumaticskinlesions
AT gargesharmony topicalretapamulininthemanagementofinfectedtraumaticskinlesions